A major step forward for strengthening the Greek medical cannabis industry and producing innovative pharmaceutical products.
Curity Pharma is pleased to announce that it has officially received its operating license from the relevant regulatory authorities of the Ministries of Development, Health, and Rural Development. This approval marks a significant milestone for the company, as it allows the immediate start of full operations at its vertically integrated medical cannabis facility, which will develop advanced pharmaceutical solutions designed to meet the evolving needs of patients.
Curity Pharma’s new Good Manufacturing Practice (GMP) complaint facility is fully equipped with cutting-edge technology, in accordance with the highest European standards of quality and safety. Curity Pharma has invested in building a specialized team of scientists, technicians, researchers, and pharmaceutical industry professionals to meet the growing demands of the European market. The company’s workforce and co-founders remain dedicated and focused on their mission to deliver innovative, reliable medical cannabis products that address the needs of patients and provide solutions for healthcare professionals.
Manos Chatiras, co-founder, chairman, and CEO of Curity Pharma stated: “This license marks the beginning of a new chapter for Curity Pharma and the medical cannabis industry. Greece is becoming an important player in the European medical cannabis sector, driving solutions based on science and advanced technology. Our vision for developing and producing innovative therapies is now coming to life, and we are ready to implement our strategy to offer the best therapeutic solutions to Greek patients, while also executing our export plan to establish Greek medical cannabis as a reference point across Europe.”
